
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6627888/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0154321.	3.2	19
2	Practices of therapeutic drug monitoring in tuberculosis: an international survey. European Respiratory Journal, 2022, 59, 2102787.	6.7	11
3	Country-specific approaches to latent tuberculosis screening targeting migrants in EU/EEA* countries: A survey of national experts, September 2019 to February 2020. Eurosurveillance, 2022, 27, .	7.0	3
4	What the snake leaves in its wake: Functional limitations and disabilities among snakebite victims in Ghanaian communities. PLoS Neglected Tropical Diseases, 2022, 16, e0010322.	3.0	6
5	Predominance of CTX-M-15-producing ST131 strains among ESBL-producing <i>Escherichia coli</i> isolated from asylum seekers in theÂNetherlands. Journal of Antimicrobial Chemotherapy, 2021, 76, 70-76.	3.0	8
6	†The medicine is not for sale': Practices of traditional healers in snakebite envenoming in Ghana. PLoS Neglected Tropical Diseases, 2021, 15, e0009298.	3.0	25
7	Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana. BMC Infectious Diseases, 2021, 21, 331.	2.9	3
8	Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2021, 21, 1701-1712.	9.1	32
9	Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet, The, 2020, 395, 1259-1267.	13.7	71
10	High varicella zoster virus susceptibility in Caribbean island populations: Implications for vaccination. International Journal of Infectious Diseases, 2020, 94, 16-24.	3.3	3
11	Pharmacologic management of <i>Mycobacterium ulcerans</i> infection. Expert Review of Clinical Pharmacology, 2020, 13, 391-401.	3.1	16
12	Patients and Medical Staff Attitudes Toward the Future Inclusion of eHealth in Tuberculosis Management: Perspectives From Six Countries Evaluated using a Qualitative Framework. JMIR MHealth and UHealth, 2020, 8, e18156.	3.7	5
13	A scabies outbreak in the North East Region of Ghana: The necessity for prompt intervention. PLoS Neglected Tropical Diseases, 2020, 14, e0008902.	3.0	8
14	Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa. PLoS Neglected Tropical Diseases, 2019, 13, e0007866.	3.0	8
15	Sensitivity and specificity of an electronic nose in diagnosing pulmonary tuberculosis among patients with suspected tuberculosis. PLoS ONE, 2019, 14, e0217963.	2.5	24
16	Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis. Clinical Pharmacokinetics, 2019, 58, 1445-1454.	3.5	19
17	The paediatric participation scale measuring participation restrictions among former Buruli Ulcer patients under the age of 15 in Ghana and Benin: Development and first validation results. PLoS Neglected Tropical Diseases, 2019, 13, e0007273.	3.0	2
18	Sensitivity and specificity of routine diagnostic work-up for tuberculosis in lung clinics in Yogyakarta, Indonesia: a cohort study. BMC Public Health, 2019, 19, 363.	2.9	15

#	Article	IF	CITATIONS
19	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. Therapeutic Drug Monitoring, 2019, 41, 59-65.	2.0	5
20	Asylum seekers' perspectives on vaccination and screening policies after their arrival in Greece and The Netherlands. PLoS ONE, 2019, 14, e0226948.	2.5	15
21	The public health control of scabies: priorities for research and action. Lancet, The, 2019, 394, 2068.	13.7	3
22	A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clinical Pharmacokinetics, 2019, 58, 747-766.	3.5	53
23	High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
24	Proportion of asylum seekers carrying multi-drug resistant microorganisms is persistently increased after arrival in the Netherlands. Antimicrobial Resistance and Infection Control, 2019, 8, 6.	4.1	12
25	National approaches to the vaccination of recently arrived migrants in Europe: A comparative policy analysis across 32 European countries. Travel Medicine and Infectious Disease, 2019, 27, 33-38.	3.0	23
26	Risk of Measles and Diphtheria Introduction and Transmission on Bonaire, Caribbean Netherlands, 2018. American Journal of Tropical Medicine and Hygiene, 2019, 101, 237-241.	1.4	6
27	In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1312-1321.	1.4	9
28	Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 650-656.	9.1	31
29	Screening for infectious diseases of asylum seekers upon arrival: the necessity of the moral principle of reciprocity. BMC Medical Ethics, 2018, 19, 16.	2.4	11
30	Risk factors contributing to a low darunavir plasma concentration. British Journal of Clinical Pharmacology, 2018, 84, 456-461.	2.4	4
31	Treatment for Buruli ulcer: the long and winding road to antimicrobials-first. The Cochrane Library, 2018, 12, ED000128.	2.8	5
32	Efficacy of ivermectin mass-drug administration to control scabies in asylum seekers in the Netherlands: A retrospective cohort study between January 2014 – March 2016. PLoS Neglected Tropical Diseases, 2018, 12, e0006401.	3.0	28
33	Divergent approaches in the vaccination of recently arrived migrants to Europe: a survey of national experts from 32 countries, 2017. Eurosurveillance, 2018, 23, .	7.0	36
34	Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug–Resistant Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2018, 98, 376-378.	1.4	1
35	Virulence potential of Staphylococcus aureus isolates from Buruli ulcer patients. International Journal of Medical Microbiology, 2017, 307, 223-232.	3.6	15
36	Neurological and functional recovery inÂtuberculosis patients with spinal cordÂinjury in The Netherlands. NeuroRehabilitation, 2017, 40, 439-445.	1.3	8

#	Article	IF	CITATIONS
37	Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. British Journal of Clinical Pharmacology, 2017, 83, 2325-2329.	2.4	5
38	Methicillin Resistant Staphylococcus aureus Transmission in a Ghanaian Burn Unit: The Importance of Active Surveillance in Resource-Limited Settings. Frontiers in Microbiology, 2017, 8, 1906.	3.5	11
39	Yield of yearly routine physical examination in HIV-1 infected patients is limited: A retrospective cohort study in the Netherlands. PLoS ONE, 2017, 12, e0179539.	2.5	Ο
40	High prevalence of MRSA and ESBL among asylum seekers in the Netherlands. PLoS ONE, 2017, 12, e0176481.	2.5	33
41	Epidemiology of Staphylococcus aureus in a burn unit of a tertiary care center in Ghana. PLoS ONE, 2017, 12, e0181072.	2.5	25
42	Former Buruli Ulcer Patients' Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management. PLoS Neglected Tropical Diseases, 2016, 10, e0005261.	3.0	21
43	High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana. International Journal of Mycobacteriology, 2016, 5, 226-230.	0.6	22
44	The Application of Modern Dressings to Buruli Ulcers: Results from a Pilot Implementation Project in Ghana. American Journal of Tropical Medicine and Hygiene, 2016, 95, 60-62.	1.4	9
45	Experiences of Pain and Expectations for Its Treatment Among Former Buruli Ulcer Patients. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1011-1015.	1.4	8
46	Poverty-Related Diseases Attack Simultaneously. American Journal of Tropical Medicine and Hygiene, 2016, 94, 939-940.	1.4	1
47	Multidrug-Resistant Tuberculosis Complicated by Nosocomial Infection with Multidrug-Resistant Enterobacteriaceae. American Journal of Tropical Medicine and Hygiene, 2016, 94, 517-518.	1.4	4
48	Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 703-710.	3.0	41
49	Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli Ulcer. PLoS Neglected Tropical Diseases, 2016, 10, e0004594.	3.0	22
50	High Prevalence of Infectious Diseases and Drug-Resistant Microorganisms in Asylum Seekers Admitted to Hospital; No Carbapenemase Producing Enterobacteriaceae until September 2015. PLoS ONE, 2016, 11, e0154791.	2.5	30
51	Pain Associated with Wound Care Treatment among Buruli Ulcer Patients from Ghana and Benin. PLoS ONE, 2015, 10, e0119926.	2.5	10
52	Molecular Characterization of Staphylococcus aureus Isolates Transmitted between Patients with Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0004049.	3.0	12
53	Assessment and Treatment of Pain during Treatment of Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0004076.	3.0	8
54	The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. European Respiratory Journal, 2015, 45, 569-571.	6.7	20

#	Article	IF	CITATIONS
55	In-vitro Activity of Avermectins against Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2015, 9, e0003549.	3.0	46
56	Genetic Diversity of Staphylococcus aureus in Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0003421.	3.0	21
57	Buruli Ulcer Control in a Highly Endemic District in Ghana: Role of Community-Based Surveillance Volunteers. American Journal of Tropical Medicine and Hygiene, 2015, 92, 115-117.	1.4	35
58	The Never Ending Struggle Against Development of Drug Resistance. Clinical Infectious Diseases, 2015, 61, 137-138.	5.8	0
59	Persisting Social Participation Restrictions among Former Buruli Ulcer Patients in Ghana and Benin. PLoS Neglected Tropical Diseases, 2014, 8, e3303.	3.0	27
60	Good Quality of Life in Former Buruli Ulcer Patients with Small Lesions: Long-Term Follow-up of the BURULICO Trial. PLoS Neglected Tropical Diseases, 2014, 8, e2964.	3.0	18
61	Long Term Streptomycin Toxicity in the Treatment of Buruli Ulcer: Follow-up of Participants in the BURULICO Drug Trial. PLoS Neglected Tropical Diseases, 2014, 8, e2739.	3.0	56
62	Contribution of the Community Health Volunteers in the Control of Buruli Ulcer in Bénin. PLoS Neglected Tropical Diseases, 2014, 8, e3200.	3.0	38
63	Psychometric Properties of the Participation Scale among Former Buruli Ulcer Patients in Ghana and Benin. PLoS Neglected Tropical Diseases, 2014, 8, e3254.	3.0	10
64	Compliance with Antimicrobial Therapy for Buruli Ulcer. Antimicrobial Agents and Chemotherapy, 2014, 58, 6340-6340.	3.2	9
65	Raltegravir and rifampicin in patients with HIV and tuberculosis. Lancet Infectious Diseases, The, 2014, 14, 1046-1047.	9.1	3
66	Management of <scp>BU</scp> – <scp>HIV</scp> coâ€infection. Tropical Medicine and International Health, 2014, 19, 1040-1047.	2.3	14
67	Wound Care in Buruli Ulcer Disease in Ghana and Benin. American Journal of Tropical Medicine and Hygiene, 2014, 91, 313-318.	1.4	28
68	Oral treatment for patients with Buruli ulcer co-infected with HIV. Aids, 2014, 28, 797-798.	2.2	2
69	Variability of antibiotic susceptibility and toxin production of Staphylococcus aureus strains isolated from skin, soft tissue, and bone related infections. BMC Microbiology, 2013, 13, 188.	3.3	45
70	Towards Rational Use of Antibiotics for Suspected Secondary Infections in Buruli Ulcer Patients. PLoS Neglected Tropical Diseases, 2013, 7, e2010.	3.0	24
71	Serum Levels of Neopterin during Antimicrobial Treatment for Mycobacterium ulcerans Infection. American Journal of Tropical Medicine and Hygiene, 2013, 89, 498-500.	1.4	5
72	Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis. JAMA - Journal of the American Medical Association, 2013, 309, 1251.	7.4	421

#	Article	IF	CITATIONS
73	Perceptions on the Effectiveness of Treatment and the Timeline of Buruli Ulcer Influence Pre-Hospital Delay Reported by Healthy Individuals. PLoS Neglected Tropical Diseases, 2013, 7, e2014.	3.0	14
74	Paradoxical Responses After Start of Antimicrobial Treatment in Mycobacterium ulcerans Infection. Clinical Infectious Diseases, 2012, 54, 519-526.	5.8	91
75	Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine. PLoS Neglected Tropical Diseases, 2011, 5, e1436.	3.0	29
76	Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet, The, 2010, 375, 664-672.	13.7	258
77	Antimicrobial drugs for Buruli ulcer – Authors' reply. Lancet, The, 2010, 375, 1873-1874.	13.7	2
78	No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis. Clinical Rheumatology, 2009, 28, 825-833.	2.2	27
79	Functional Limitations after Surgical or Antibiotic Treatment for Buruli Ulcer in Benin. American Journal of Tropical Medicine and Hygiene, 2009, 81, 82-87.	1.4	49
80	Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. American Journal of Tropical Medicine and Hygiene, 2009, 81, 82-7.	1.4	34
81	Healthcare seeking behaviour for Buruli ulcer in Benin: a model to capture therapy choice of patients and healthy community members. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 912-920.	1.8	48
82	Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Research and Therapy, 2008, 10, R49.	3.5	59
83	Sinus node function in children with congenital complete atrioventricular block. Europace, 2007, 9, 844-847.	1.7	5
84	Longitudinal Echocardiographic Followâ€Up in Children with Congenital Complete Atrioventricular Block. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1339-1343.	1.2	28
85	Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. Genes and Immunity, 2006, 7, 185-189.	4.1	71
86	Mean glucose level is not an independent risk factor for mortality in mixed ICU patients. Intensive Care Medicine, 2006, 32, 435-438.	8.2	31
87	Reply to the comment by Dr. Tayek. Intensive Care Medicine, 2006, 32, 1660-1660.	8.2	0
88	Mixing Up All the Results. Critical Care Medicine, 2005, 33, 701-702.	0.9	0
89	Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 196-201.	1.8	29
90	Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Tropical Medicine and International Health, 2005, 10, 1251-1257.	2.3	50

#	Article	IF	CITATIONS
91	Cytokine Responses to Stimulation of Whole Blood from Patients with Buruli Ulcer Disease in Ghana. Vaccine Journal, 2005, 12, 125-129.	3.1	47
92	Risk Factors for Buruli Ulcer Disease (Mycobacterium ulcerans Infection): Results from a Case-Control Study in Ghana. Clinical Infectious Diseases, 2005, 40, 1445-1453.	5.8	138
93	Quality of interhospital transport of critically ill patients: a prospective audit. Critical Care, 2005, 9, R446.	5.8	123
94	RELIABILITY AND VALIDITY OF THE BURULI ULCER FUNCTIONAL LIMITATION SCORE QUESTIONNAIRE. American Journal of Tropical Medicine and Hygiene, 2005, 72, 449-452.	1.4	22
95	Mycobacterium ulcerans disease. Bulletin of the World Health Organization, 2005, 83, 785-91.	3.3	114
96	Reliability and validity of the Buruli ulcer functional limitation score questionnaire. American Journal of Tropical Medicine and Hygiene, 2005, 72, 449-52.	1.4	9
97	Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. Vaccine Journal, 2004, 11, 387-391.	2.6	21
98	DEVELOPMENT OF A QUESTIONNAIRE ASSESSING BURULI ULCER–INDUCED FUNCTIONAL LIMITATION. American Journal of Tropical Medicine and Hygiene, 2004, 70, 318-322.	1.4	20
99	BURULI ULCER AND SCHISTOSOMIASIS: NO ASSOCIATION FOUND. American Journal of Tropical Medicine and Hygiene, 2004, 71, 318-321.	1.4	13
100	Development of a questionnaire assessing Buruli ulcer-induced functional limitation. American Journal of Tropical Medicine and Hygiene, 2004, 70, 318-22.	1.4	12
101	Buruli ulcer and schistosomiasis: no association found. American Journal of Tropical Medicine and Hygiene, 2004, 71, 318-21.	1.4	4
102	Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli Ulcer Functional Limitation Score. Tropical Medicine and International Health, 2003, 8, 90-96.	2.3	41
103	Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Tropica, 2003, 88, 51-56.	2.0	40
104	Mycolactones and Mycobacterium ulcerans disease. Lancet, The, 2003, 362, 1062-1064.	13.7	78
105	Analysis of an IS 2404 -Based Nested PCR for Diagnosis of Buruli Ulcer Disease in Regions of Ghana Where the Disease Is Endemic. Journal of Clinical Microbiology, 2003, 41, 794-797.	3.9	38
106	Histopathologic Features of <i>Mycobacterium ulcerans</i> Infection. Emerging Infectious Diseases, 2003, 9, 651-656.	4.3	134
107	Skin ulcers misdiagnosed as pyoderma gangrenosum. New England Journal of Medicine, 2003, 348, 1064-6; author reply 1064-6.	27.0	0
108	The African challenge. Lancet, The, 2002, 359, 1527-1528.	13.7	1

7

#	Article	IF	CITATIONS
109	Availability of drugs to admitted patients in Yemeni public hospitals. European Journal of Clinical Pharmacology, 2002, 58, 79-80.	1.9	0
110	Beliefs and attitudes toward Buruli ulcer in Ghana American Journal of Tropical Medicine and Hygiene, 2002, 67, 207-213.	1.4	131
111	Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Tropical Medicine and International Health, 2001, 6, 554-562.	2.3	74